Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cancer Research Technology Selects Maybridge Fragments for Lead Discovery Programmes

Published: Friday, May 22, 2009
Last Updated: Friday, May 22, 2009
Bookmark and Share
CRT purchases 2,000 Maybridge Fragments as the foundation of its new fragment screening library.

Thermo Fisher Scientific has announced that Cancer Research Technology (CRT) has purchased 2,000 Maybridge Fragments as the foundation of its new fragment screening library. Wholly owned by the internationally renowned charity, Cancer Research UK, CRT is a specialist oncology-focused development and commercialization company.

Selected for its high quality, the Maybridge Fragment Collection will be used in CRT’s established discovery laboratories in London and Cambridge, for fragment-based screening, a key technology to accelerate the identification of drug leads against novel cancer targets.

“Having reviewed several vendor catalogues with a focus on fragment collections for a discrete selection of heterocyclic small molecules with suitable properties, we ultimately chose the Maybridge Fragment Collection due to its superior overall fit to our requirements,” explained Dr. Martin Swarbrick, Group Leader, Medicinal Chemistry, at CRT. “A good fit to ‘Rule-of-Three’ principles for physicochemical properties was essential, as well as lead-likeness and ‘drug-ability’.”

Other key features of the Maybridge Fragment collection that influenced the CRT selection process include its high compound purity and chemical diversity, which is supported by related synthons elsewhere in the Maybridge catalogue. The availability of related building blocks featuring the same fragments from Maybridge stock facilitates the construction of a library around chosen core fragments for hit-to-lead work and further optimization.

“Other factors in our decision to purchase the Maybridge Fragment selection were their immediate and reliable availability for prompt follow up work, as well as the favorable pricing,” added Swarbrick.

“We are very proud to have been selected by such an eminent cancer technology transfer company due to the quality, diversity and flexibility of our Fragment Collection,” said Dr.Mick Durrant, Director of Business Development for Maybridge products at Thermo Fisher Scientific. “We pride ourselves on our choice of off-the-shelf collections and the ability to pick from our carefully selected fragment lists. This enables our customers to create their own bespoke libraries, giving them both convenience and complete control over their fragment screening programmes to ultimately accelerate lead generation.”

The Maybridge Fragment collection is a convenient source of pre-selected, high quality building blocks which is a distillation of Maybridge’s combined expertise in heterocyclic compound design. Over 30,000 compounds have been assembled to form a pool from which researchers can build their own customized fragment libraries. This collection has been selected for purity, low molecular weight and absence of inappropriate functionality. All compounds are easily re-supplied and available custom weighed in mgs or µmols.

Many of the Maybridge Fragments are fully “Rule-of-Three” compliant, which means that the physicochemical properties of these fragments are optimal; therefore increasing the probability of future “hit” successes. Consequently, Maybridge Fragments provide an ideal starting point for a lead optimization drug discovery programme and the ultimate evolution of a new molecule in the drug discovery process.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ATCC, CDC and Thermo Partner on Public Health RT-PCR Assay
New technology supports HIV-1 drug resistance surveillance in resource-limited countries.
Wednesday, June 25, 2014
Biodesign Institute, Thermo Fisher Partner on $9M Radiation Test
Partnership enters a new, $9M phase of a project to produce a diagnostic test to rapidly measure an individual’s level of absorption of ionizing radiation.
Wednesday, June 04, 2014
Thermo, Nuclea Biotechnologies Collaborate to Develop Diabetes Markers
Companies pooling their expertise to develop novel multiplexed research methods for high-throughput quantification of native insulin and its therapeutic analogs.
Monday, June 02, 2014
Thermo Completes Life Tech Acquisition
The completion of the transaction follows the receipt of all required regulatory approvals.
Tuesday, February 04, 2014
Thermo Receives EC Clearance for Life Tech Acquisition
Thermo Fisher Scientific announced that it has received approval from the European Commission (EC) for its pending acquisition of Life Technologies Corporation.
Tuesday, November 26, 2013
Thermo Scientific Enters into a Long-Term Agreement with Fujirebio
Combination of Thermo Scientific B•R•A•H•M•S PCT assay and Lumipulse platforms to test patients suspected of having sepsis.
Thursday, November 22, 2012
Thermo Fisher Scientific Announces Collaboration to Establish New Tokyo Biomarker Research Center
Thermo Fisher Scientific Inc., today announced a landmark collaboration that aims to introduce mass spectrometry-based workflows and technologies into Japan to advance personalized medicine and healthcare.
Monday, July 26, 2010
Thermo Fisher Scientific’s Mass Spectrometry Technology Helps Children’s Hospital Boston Isolate Biomarker for Acute Pediatric Appendicitis
Children’s Hospital research team believes discovery will lead to more accurate, efficient diagnosis
Tuesday, December 15, 2009
Thermo Fisher Scientific Collaborates with the Institute of Cancer Research to Create Proteomics Laboratory
The ICR's new, proteomics laboratory is equipped with a complete Thermo Scientific proteomics workflow.
Friday, July 24, 2009
Thermo Fisher Scientific Wins Innovation Award in Informatics for Second Consecutive Year
Thermo Scientific Nautilus LIMS for Biobanks increases throughput at Hunt Research Centre and Biobank.
Thursday, July 16, 2009
Thermo Fisher Scientific Welcomes New Members to RNAi Global Initiative
The new member institutions include the Children's Hospital of Eastern Ontario Research Institute and the University of Leiden in Amsterdam.
Monday, March 02, 2009
Thermo Fisher Scientific Joins Microsoft in the Bio IT Alliance
The BioIT Alliance is an organization of more than 40 pharmaceutical, biotech, hardware and software companies working together to realize the potential of personalized medicine.
Friday, February 02, 2007
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Study Identifies the Off Switch for Biofilm Formation
New discovery could help prevent the formation of infectious bacterial films on hospital equipment.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Combo Tool
Joining molecular components expands ability to manipulate genes in specific cell types.
Team Identifies Structure of Tumor-Suppressing Protein
An international group of researchers led by Carnegie Mellon University physicists Mathias Lösche and Frank Heinrich have established the structure of an important tumor suppressing protein, PTEN.
Genes Associated With Improved Survival for Pancreatic Cancer Patients
Use of non-invasive liquid biopsies could predict in which patients the cancer could recur following surgery.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!